Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GTXI and MRK combined their selective androgen receptor modulator (SARM) programs and partnered to discover, develop and
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury